Jamieson is pleased to announce that it has advised the management team of Biocomposites on a re-investment in Biocomposites. As part of the transaction TA, Biocomposites’ majority shareholder since 2017, will reinvest in the Company alongside new investor Novo Holdings and Biocomposites’ management. The transaction gives TA and Novo Holdings shared control of Biocomposites.
Headquartered in the UK, Biocomposites is an international medical devices company that engineers, manufactures and markets leading products for infection management in bone and soft tissue.
Mike Harris, CEO of Biocomposites, commented:
“Jamieson’s support in negotiating the management incentive package was invaluable. They were an excellent resource, were there around the clock in a fast-moving process, and provided helpful guidance throughout.”
Stuart Coventry, Jonny Jones and Alexander Wilson advised Mike Harris and the management team on the terms of their continued investment in the company.
